HDAC overexpression has been observed in many cancers and is, therefore, considered new target of cancer therapy; indeed, four HDAC inhibitors are approved for clinical use in T-cell lymphoma and multiple myeloma12. The gene discussed is HDAC9; the disease is T-cell non-Hodgkin lymphoma.